Patient P-01678
Therapy response
Stable
Tolerance
Stable
GI state
Favorable
Inflammatory state
Stable
Nutritional resilience
Declining
Discontinuation risk
55%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S14
- Day 31 NP-02 recommended — Dietary Support Protocol NP-02
- Day 32 Patient accepted — Started NP-02 in the companion
- Day 42 GI symptom burden −17% vs expected — Dietary Support Protocol NP-02
- Day 46 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 48 Tolerance state changed — Unstable → Improving
- Day 53 SC-12 recommended — Supportive Compound SC-12
- Day 54 Patient declined — Not now
- Day 56 GI-04 recommended — GI Support Protocol GI-04
- Day 57 Patient accepted — Started GI-04 in the companion
- Day 65 GI symptom burden −38% vs expected — GI Support Protocol GI-04
- Day 71 Tolerance state changed — Unstable → Improving
What changed?
Trajectory began diverging from predicted response on Day 46.
Primary contributors, last 14 days
- Nutritional resilience-7
- Inflammatory activity-3
- Treatment adherence-2
What helped?
- Dietary Support Protocol NP-02Day 31Result: symptom burden −17%
- Supportive Compound SC-12Day 53Declined by patient
- GI Support Protocol GI-04Day 56Result: symptom burden −38%
LIFE OS recommendation
Supportive Compound SC-12
65%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 85% showed improvement
- median effect visible after 6 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 32/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Mucosal barrier integrity ↓70
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- WearableSleep 5.5 h, below personal baseline
- Inflammatory signalling ↓25
- BloodInflammatory load index 42
- Drug metabolism and exposure ↑20
- BloodToxicity index 44
- Autonomic recovery ↓20
- WearableShort sleep window
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- CYP2D6 Normal metabolizerExpected exposure
Microbiome
Shannon diversity 2.6 · butyrate capacity 32/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumNormal
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 48 ms
- Sleep
- 5.8 h
- Steps
- 6,149
- Resting HR
- 65 bpm
Daily log: GI score 36, nutritional resilience 49, adherence 55.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Log the daily check-in; one line is enough
- Keep the current walking rhythm
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- No additional supplements this week
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.